Federated Hermes’s Lantern Pharma LTRN Stock Holding History

Federated Hermes’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-74	Closed	-$346	–	2116
2024 Q2	$346	Buy	+74	New	+$445	﹤0.01%	1981

Other funds holding LTRN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Federated Hermes's LTRN Position: Q3 2024 in Review

Federated Hermes sold out of Lantern Pharma (LTRN) in Q3 2024, closing a stake of 74 shares — an estimated $346 sold.

Federated Hermes first reported a position in LTRN in Q2 2024 and held it in 1 quarter. The position peaked at $346 in Q2 2024. 31 funds tracked by Wall St. Rank hold LTRN as of Q3 2024.

Federated Hermes reported no remaining Lantern Pharma position as of Q3 2024 after selling out during the quarter.
Federated Hermes sold 74 Lantern Pharma shares in Q3 2024, an estimated $346.
Federated Hermes first reported a position in Lantern Pharma in Q2 2024 and held it in 1 quarter.
Federated Hermes's Lantern Pharma position peaked at $346 in Q2 2024.
31 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2024.

Based on Federated Hermes's 13F filing for Q3 2024, filed 13 Nov 2024.